8 results about "Gabapentin" patented technology

The invention discloses application of Gabapentin in improvement of cognitive impairment of Alzheimer's disease. An application model is an APP / PS1 Alzheimer's disease animal model, a control group is a wild type mouse, Gabapentin granules are dissolved with normal saline and used in an intraperitoneal injection mode, the dosage of single administration is 50 mg / kg, administration is performed for 7 days each month, and then behavioral detection is performed. By detecting and analyzing the actual application result, the effect description of the Gabapentin on the improvement of the AD scene memory is obtained. When the medicine is subjected to intraperitoneal injection and administration, the excessive excitability of neurons can be reduced, the scene memory function of AD mice can be improved, a new use method of Gabapentin is expanded, and a new thought is provided for treatment of AD.

The present invention relates to the technical field of pharmaceutical detection, and particularly relates to an analytical method for the impurity profile of megalol gabapentin besylate raw material drugs. The method uses high performance liquid chromatography with a chiral complexing agent added to the mobile phase for determination. The liquid chromatography conditions are as follows: mobile phase A includes a phosphate-chiral complexing agent buffer solution, mobile phase B includes acetonitrile and water, and gradient elution is adopted; the flow rate is 0.5 - 2.0 mL / min; the chromatographic column stationary phase filler is achiral silane-bonded silica gel; the column temperature is 15°C - 55°C; the detection wavelength is 190 nm - 230 nm. This method has the advantages of simple operation, low cost, good selectivity, high accuracy, and strong universality. It is suitable for the study of the impurity profile of megalol gabapentin besylate raw material drugs, thereby effectively controlling the product quality. At the same time, it can be extended to the study of the impurity profiles of other amino acids and their similar drugs.

The present invention provides methods of treating cannabis withdrawal syndrome and other cannabis related conditions, including cannabis use disorder, in a subject, comprising administering to the subject in need thereof an effective amount of a cannabinoid or an effective amount of a cannabinoid and an effective amount of a second active agent, such as gabapentin or a gabapentin analog.

The present disclosure provides pharmaceutical compositions and methods for the treatment of a sleep disorder such as insomnia, by inducing, extending, or consolidating sleep. The compositions comprise mirtazapine, or a salt or derivative thereof, optionally in combination with and gabapentin, or a salt or derivative thereof, at relatively low doses of each such that the combination provides useful therapeutic benefit while avoiding unwanted side effects associated with treatment using alternative pharmaceutical agents.

Described are room temperature stable gabapentin powders that can be readily reconstituted in water for dosing as an oral solution. The gabapentin powder formulations have improved chemical stability, palatability, portability, storage, and ease of administration, as well as fast reconstitution time, and prolonged product shelf life. The gabapentin powder formulations comprise gabapentin, a sugar alcohol, one or more artificial sweeteners and, optionally, a flavoring agent.

The present disclosure provides pharmaceutical compositions and methods for the treatment of a sleep disorder such as insomnia, by inducing, extending, or consolidating sleep. The compositions comprise mirtazapine, or a salt or derivative thereof, optionally in combination with and gabapentin, or a salt or derivative thereof, at relatively low doses of each such that the combination provides useful therapeutic benefit while avoiding unwanted side effects associated with treatment using alternative pharmaceutical agents.

A composition for treatment of pain and inflammation in humans includes 4.0-10.0% Diclofenac Sodium by weight, 2.0-6.0% Gabapentin by weight, 1.0-2.0% Baclofen by weight, and 2.0-5.0% Cyclobenzaprine by weight. Other compositions are also disclosed.

The present invention relates to a pharmaceutical composition comprising (a) (i) a combination of Trazodone or a salt thereof, and (ii) Gabapentin or Pregabalin or Milnacian or a salt thereof or a prodrug thereof, and (b) at least one pharmaceutically acceptable excipient, for the treatment of neuropathic pain, wherein the pharmaceutical composition comprises Trazodone:Gabapentin or Pregabalin or Milnacian in a weight ratio of between 1:40 and 1:100, preferably below 1:40 and up to 1:100.